Update on mental health issues in patients with HIV infection

Current Infectious Disease Reports

Volumn 11, Issue 2, 2009, Pages 163-169

  Vlassova, Natalia ^a   Angelino, Andrew F ^a   Treisman, Glenn J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; EFAVIRENZ; LAMOTRIGINE; LITHIUM SALT; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; VALPROIC ACID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; BIPOLAR DISORDER; BRAIN DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; DELIRIUM; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT COMPLIANCE; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT;

EID: 62549104235     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0024-4     Document Type: Review

References (70)

1. Kubler-Ross E: On Death and Dying. New York: Macmillan; 1969.
2. McHugh PR, Slavney PR: The Perspectives of Psychiatry, edn 2. Baltimore: The Johns Hopkins University Press; 1998.
3. Angelino AF, Treisman GJ: Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001, 33: 847-856.
4. Atkinson JH, Heaton RK, Patterson TL, et al.; HNRC Group: Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2008, 108: 225-234.
5. Cysique LA, Deutsch R, Atkinson JH, et al.; HNRC Group: Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007, 13: 1-11.
6. Gibbie T, Hay M, Hutchison CW, Mijch A: Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health 2007, 4: 227-232.
7. Rabkin JG, McElhiney MC, Ferrando SJ: Mood and substance use disorders in older adults with HIV/AIDS: Methodological issues and preliminary evidence. AIDS 2004, 18(Suppl 1): S43-S48.
8. Narrow WE, Rae DS, Robins LN, Regier DA: Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002, 59: 115-123.
9. Asch SM, Kilbourne AM, Gifford AL, et al.; HCSUS Consortium: Underdiagnosis of depression in HIV: Who are we missing? J Gen Intern Med 2003, 18: 450-460.
10. Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV-positive individuals with depression: A systematic review and meta-analysis. AIDS Patient Care STDS 2005, 19: 813-822.
11. Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: A systematic review and meta-analysis. AIDS Patient Care STDS 2007, 21: 732-739.
12. Waldrop-Valverde D, Valverde E: Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 2005, 19: 326-334.
13. Sledjeski EM, Delahanty DL, Bogart LM: Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS 2005, 19: 728-736.
14. Alciati A, Gallo L, Monforte AD, et al.: Major depression-related immunological changes and combination antiretroviral therapy in HIV-seropositive patients. Hum Psychopharmacol 2007, 22: 33-40.
15. Cruess DG, Douglas SD, Petitto JM, et al.: Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 2005, 162: 2125-2130.
16. Pieper AA, Treisman, GJ: Drug treatment of depression in HIV-positive patients: Safety considerations. Drug Safety 2005, 28: 753-762.
17. Thompson A, Silverman B, Dzeng K, Treisman GJ: Psychotropic medications and HIV. Clin Infect Dis 2006, 42: 1305-1310.
18. Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E: Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry 2006, 163: 1349-1354.
19. Maxwell S, Scheftner WA, Kessler HA, Busch K: Manic syndrome associated with zidovudine treatment. JAMA 1988, 259: 3406-3407.
20. Brouilette MJ, Routy JP: Abacavir sulfate and mania in HIV. Am J Psychiatry 2007, 164: 979-980.
21. Shah MD, Balderson K: A manic episode associated with efavirenz therapy for HIV infection. AIDS 2003, 17: 1713-1714.
22. Weisler RH, Keck PE Jr, Swann AC, et al.; SPD417 Study Group: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005, 66: 323-330.
23. Sajatovic M, Ramsay E, Nanry K, Thompson T: Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. Int J Geriatr Psychiatry 2007, 22: 945-950.
24. Ferrando SJ, Nims C: HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy. Psychosomatics 2006, 47: 170-174.
25. Regier DA, Farmer ME, Rae DS, et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264: 2511-2518.
26. Himelhoch S, McCarthy JF, Ganoczy D, et al.: Understanding associations between serious mental illness and HIV among patients in the VA Health System. Psychiatr Serv 2007, 58: 1165-1172.
27. Cournos F, Guido JR, Coomaraswamy S, et al.: Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry 1994, 151: 228-232.
28. Koen L, Uys S, Niehaus DJ, Emsley RA: Negative symptoms and HIV/AIDS risk-behavior knowledge in schizophrenia. Psychosomatics 2007, 48: 128-134.
29. Bagchi A, Sambamoorthi U, McSpiritt E, et al.: Use of antipsychotic medications among HIV-infected individuals with schizophrenia. Schizophr Res 2004, 71: 435-444.
30. Ziedonis DM, Smelson D, Rosenthal RN, et al.: Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. J Psychiatr Pract 2005, 11: 315-339.
31. Aylward EH, Brettschneider PD, McArthur JC, et al.: Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 1995, 152: 987-994.
32. Anthony IC, Ramage SN, Carnie FW, et al.: Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005, 64: 529-536.
33. Hauser KF, El-Hage N, Stiene-Martin A, et al.: HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007, 100: 567-586.
34. Shiramizu B, Gartner S, Williams A, et al.: Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005, 19: 45-52.
35. Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Ann Neurol 1995, 38: 755-762.
36. Bhaskaran K, Mussini C, Antinori A, et al.; CASCADE Collaboration: Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008, 63: 213-221.
37. Mahajan SD, Aalinkeel R, Sykes DE, et al.: Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008, 1203: 133-148.
38. Dhillon NK, Peng F, Bokhari S, et al.: Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: Implications for HIV-dementia. J Neuroimmune Pharmacol 2008, 3: 52-56.
39. Letendre SL, Marquie-Beck J, Ellis RJ, et al.; CHARTER Group: The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007, 2: 120-127.
40. Letendre S, Marquie-Beck J, Capparelli E, et al.; CHARTER Group: Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65: 65-70.
41. Muñoz-Moreno JA, Rodríguez C, Prats A, et al.: Recommended earlier initiation of ART based on nadir CD4 cell count as a risk factor for HIV-related neurocognitive impairment. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25-28, 2007.
42. Uldall KK, Harris VL, Lalonde B: Outcomes associated with delirium in acutely hospitalized acquired immune deficiency syndrome patients. Compr Psychiatry 2000, 41: 88-91.
43. Angelino AF, Treisman GJ: Issues in co-morbid severe mental illnesses in HIV infected individuals. Int Rev Psychiatry 2008, 20: 95-101.
44. Meagher DJ, Moran M, Raju B, et al.: Phenomenology of delirium. Assessment of 100 adult cases using standardized measures. Br J Psychiatry 2007, 190: 135-141.
45. Cohen BJ: Theory and Practice of Psychiatry. New York: Oxford University Press; 2003.
46. Eysenck HJ: Genetic and environmental contributions to individual differences: The three major dimensions of personality. J Personality 1990, 58: 245-261.
47. Costa PT Jr, Widiger TA, eds: Personality Disorders and the Five-Factor Model of Personality. Washington, DC: American Psychological Association; 1994.
48. Moore DJ, Atkinson JH, Akiskal H, et al.; HNRC Group: Temperament and risky behaviors: A pathway to HIV? J Affect Disord 2005, 85: 191-200.
49. Meade CS, Graff FS, Griffin ML, Weiss RD: HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend 2008, 92: 296-300.
50. Chander G, Himelhoch S, Moore RD: Substance abuse and psychiatric disorders in HIV-positive patients: Epidemiology and impact on antiretroviral therapy. Drugs 2006, 66: 769-789.
51. Palepu A, Tyndall M, Yip B, et al.: Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003, 32: 522-526.
52. Lucas GM, Gebo KA, Chaisson RE, et al.: Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1treatment outcomes in an urban clinic. AIDS 2002, 16: 767-774.
53. Tucker JS, Burnam MA, Sherbourne CD, et al.: Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003, 114: 573-580.
54. de Jong BC, Prentiss D, McFarland W, et al.: Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr 2005, 38: 43-46.
55. Miguez MJ, Shor-Posner G, Morales G, et al.: HIV treatment in drug abusers: Impact of alcohol use. Addict Biol 2003, 8: 33-37.
56. Wood E, Kerr T, Tyndall MW, Montaner JS: A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008, 22: 1247-1256.
57. Wood E, Hogg RS, Yip B, et al.: Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005, 19: 1189-1195.
58. Desai MM, Rosenheck RA, Desai RA: Prevalence and correlates of human immunodeficiency virus testing and posttest counseling among outpatients with serious mental illness. J Nerv Ment Dis 2007, 195: 776-780.
59. Dilley JW, Woods WJ, Loeb L, et al.: Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: Results from a randomized controlled trial using paraprofessional counselors. Acquir Immune Defic Syndr 2007, 44: 569-577.
60. Williams ML, Bowen AM, Timpson SC, et al.: HIV prevention and street-based male sex workers: An evaluation of brief interventions. AIDS Educ Prev 2006, 18: 204-215.
61. Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of group psychotherapy to reduce depressive symptoms among HIVinfected individuals: A systematic review and meta-analysis. AIDS Patient Care STDS 2007, 21: 732-739.
62. Berger S, Schad T, von Wyl V, et al.: Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS 2008, 22: 767-775.
63. Antoni MH, Carrico AW, Durán RE, et al.: Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med 2006, 68: 143-151.
64. Plotzker RE, Metzger DS, Holmes WC: Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: A potential mediating pathway. Am J Addict 2007, 16: 431-438.
65. Gwandure C: Sexual assaRlt in childhood: risk HIV and AIDS behaviours in adulthood. AIDS Care 2007, 19: 1313-1315.
66. Boarts JM, Sledjeski EM, Bogart LM, Delahanty DL: The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav 2006, 10: 253-261.
67. Vranceanu AM, Safren SA, Lu M, et al.: The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS 2008, 22: 313-321.
68. Radcliffe J, Fleisher CL, Hawkins LA, et al.: Posttraumatic stress and trauma history in adolescents and young adults with HIV. AIDS Patient Care STDS 2007, 21: 501-508.
69. Willenbring ML: Integrating care for patients with infectious, psychiatric, and substance use disorders: Concepts and approaches. AIDS 2005, 19(Suppl 3): S227-S237.
70. Himelhock S, Moore RD, Treisman GJ, Gebo KA: Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004, 37: 1457-1463.